10.01.2018 00:57:00

International Laboratories, LLC Issues Voluntary Nationwide Recall of one (1) Lot of Clopidogrel Tablets USP, 75 mg packaged in bottles of 30 tablets Due to Mislabeling

SEMINOLE, Fla., Jan. 9, 2018/PRNewswire/ -- International Laboratories, LLC is voluntarily recalling Lot# 117099A of Clopidogrel Tablets, USP 75 mg, packaged in bottles of 30 tablets, to the consumer level due to mislabeling.  The product is labeled as Clopidogrel tablets USP 75 mg but may contain Clopidogrel 75 mg or Simvastatin Tablets USP 10 mg.

Clopidogrel Tablets USP 75 mg Label image:

Missed doses of Clopidogrel increases the risk of heart attack and stroke which can be life threatening. Patients should not stop taking clopidogrel without talking to their prescribing physician. Additionally, unintentional consumption of simvastatin could include the common side effects associated with its use and may cause fetal harm when administered to a pregnant woman. Simvastatin occasionally causes myopathy which is a disease of the muscles. Finally, allergic reactions are also possible and could also be life threatening. International Laboratories, LLC also reports that to date, no complaints have been received related to this event detailing medical illnesses or harmful effects.

Clopidogrel Tablets USP 75 mgare a platelet inhibitor (blood thinner) indicated for the use in patient with acute coronary syndrome, recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke.

Clopidogrel 75mg               

Simvastatin 10 mg

Tablet Description:              

Tablet Description                                                                                                 

light-pink to pink                      

Light-pink, round

capsule shaped                        

"7153" on one side

 "TV" on one side                       

"TV" on the other side

 "7314" on the other side              


The product was distributed nationwide and delivered to the distribution centers inArkansas, Georgia, Indiana, California and Maryland, and distributed to retail stores in all US States.

International Laboratories, LLC is notifying distributors and customers by letter and is arranging for return of all recalled products.  Consumers who have purchased this product should stop using and return the product to the location of purchase for a full refund. For questions regarding return of product please call Inmar at 855-258-7280 or via email internationallabs@inmar.com  or by using mailing address Recall Coordinator 635 Vine St. Winston Salem, NC 27101 Inmar's business hours are (Monday – Friday 9 AM5 PM EST).

Consumers should also contact their physician or healthcare provider if they are experiencing any health concerns that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/international-laboratories-llc-issues-voluntary-nationwide-recall-of-one-1-lot-of-clopidogrel-tablets-usp-75-mg-packaged-in-bottles-of-30-tablets-due-to-mislabeling-300580450.html

SOURCE International Laboratories, LLC

Analysen zu Pentair PLCmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Pentair PLC 102,80 0,59% Pentair PLC